首页> 外文期刊>Asian Journal of Animal Sciences >Role of Hepatocyte Differentiated Mesenchymal Stem Cells in Treatment of Experimentally Induced Canine Liver Cirrhosis
【24h】

Role of Hepatocyte Differentiated Mesenchymal Stem Cells in Treatment of Experimentally Induced Canine Liver Cirrhosis

机译:肝细胞分化的间充质干细胞在治疗实验性犬肝硬化中的作用

获取原文
获取原文并翻译 | 示例
       

摘要

Liver cirrhosis represents the final pathway of all chronic hepatic injury. Replacement the damaged hepatocytes through cell-based therapies have been a promising therapeutic agent for tissue regeneration. This study aimed to assess the effect of treatment with Hepatocyte Differentiated Mesenchymal Stem Cells (HD-MSCs) in experimentally induced canine liver cirrhosis. Experimental induction of liver cirrhosis was done on 18 skeletally mature mongrel dogs using carbon tetrachloride (CCI4) for 16 weeks; dogs were evaluated for cirrhosis through clinical, Liver Function Tests (LFTs), ultrasonography with Portal Vein (PV) and Hepatic Vein (HV) diameter estimation and histopathological examination. Dogs were randomly allocated into one of the two study groups; Sham group: CCI4 with no HD-MSCs treatment and group II: CCI4 with HD-MSCs treatment then dogs were evaluated for the efficacy of cell treatment through clinical, LFTs, ultrasonography with PVand HVdiameter estimation, postmortem examination, histopathological examination of liver tissue and relative quantitative expression of collagen la and albumin were measured by Reverse Transcription-Polymerase Chain Reaction (RT-PCR).The HD-MSCs administration restored liver function that was confirmed by clinical, LFTs, histopathology and RT-PCR. Liver tissue ultrasonography, PV and HV diameter were improved. The study proves the ability of HD-MSCs to potentially improve cases of liver cirrhosis.
机译:肝硬化代表所有慢性肝损伤的最终途径。通过基于细胞的疗法替代受损的肝细胞已成为用于组织再生的有前途的治疗剂。这项研究旨在评估肝细胞分化的间充质干细胞(HD-MSC)在实验性诱导的犬肝硬化中的治疗效果。用四氯化碳(CCI4)对18只骨骼成熟的杂种犬进行实验性肝硬化诱导16周。通过临床,肝功能测试(LFT),门静脉曲张(PV)和肝静脉(HV)直径超声检查以及组织病理学检查对犬进行肝硬化评估。将狗随机分配到两个研究组之一中。假手术组:不使用HD-MSCs治疗的CCI4,第二组:不使用HD-MSCs治疗的CCI4,然后通过临床,LFTs,PV和HV直径超声检查,验尸检查,肝脏组织病理学检查以及通过逆转录聚合酶链反应(RT-PCR)检测胶原蛋白la和白蛋白的相对定量表达。HD-MSCs给药恢复了肝功能,这通过临床,LFT,组织病理学和RT-PCR证实。肝组织超声检查,PV和HV直径均得到改善。这项研究证明了HD-MSC具有改善肝硬化病例的能力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号